Navigation Links
Intercept Pharmaceuticals Raises $25 Million Series B Financing
Date:1/25/2010

NEW YORK, Jan. 25 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

Dr. Mark Pruzanski, founder, President and CEO commented, "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777. Genextra's strong backing will enable us to advance our clinical programs while continuing to build our pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors."

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

About INT-747 (first-in-cla
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
6. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... 10, 2011 Nephros, Inc. (OTC Bulletin Board: ... by the Food and Drug Administration ("FDA") of the 510(k) ... On August 11, 2011 Nephros submitted a new 510(k) ... disease.  On November 8, 2011 Nephros received the initial FDA ...
... N.C., Nov. 10, 2011 Max Healthcare, India,s first ... today announced organizational changes that include Dr. Ajay Bakshi ... 1, 2011. The Company also named Dr. Abha Aggarwal ... that Mr. Ranvir Bhandari would be taking the additional ...
Cached Medicine Technology:Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 2Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 3Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 4Max Healthcare Announces Organizational Changes 2
(Date:11/27/2014)... In order to enable people to adapt ... an easy way to avoid touching a toilet seat and/or ... a prototype of the patent-pending Toilet Tamer, a device that ... and/or lid in a more sanitary manner. It avoids direct ... Overall, it promotes good hygiene and peace of mind. The ...
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... 27, 2014 Dr. Ronald Receveur, who has ... a few oral health tips before patients dig into the ... and New Albany affordable cosmetic dentistry, and his ... starch and sugar. While the staff wishes everyone a happy ... for how patients can enjoy a feast that is also ...
(Date:11/27/2014)... The Little Gym, we know that being active provides ... a recent study confirmed that regular physical activity can ... Pediatrics found that “Promoting physical activity that involves ... may be important not only for health, but also ... of children; those that were engaging in regular physical ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified ... Christmas discount on PPC service. The discount will be available ... begin on 1 December 2014 and remain valid until midnight ... PPC professional working at Ethane Web Technologies says, "This is ... this big discount would make the service quite affordable for ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... speaks to you, do you see what they are saying? ... hear, but recent studies suggest that we use a variety ... speech as something we hear, see and even feel. In ... , a journal of the Association for Psychological Science, psychologist ...
... quality care at Cancer Treatment Centers of America ... of America (CTCA) has opened the nation,s first ... facility is the fourth hospital in the steadily ... Medical Center (Western) extends the comprehensive electronic health ...
... 11 /PRNewswire-USNewswire/ -- The U.S. House of ... Assisted Living Federation of America to help law ... Alert Act (H.R. 632), authored by Congressman Lloyd ... vote."We commend Congressman Doggett for his leadership. This ...
... enable more time for direct resident care, ... increase staff satisfactionPITTSBURGH, Feb. 11 Vocollect ... Partners Management Group (Preferred Care) headquartered in ... in two of its managed skilled nursing ...
... efficacy a building block for health reformWASHINGTON, Feb. ... America,s Health Insurance Plans (AHIP), today issued the ... in the Senate-passed stimulus bill:"At a time when ... serious concern for many Americans, it is critical ...
... Brain sees these as special events, even though result ... News) -- A near-win in gambling stimulates a large ... boosts a person,s motivation to gamble, according to British ... explain why gambling attracts so many people and why ...
Cached Medicine News:Health News:Read my lips: Using multiple senses in speech perception 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 3Health News:House Passes ALFA-Supported National Silver Alert Bill 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 3Health News:'Near-Wins' Boost Desire to Keep Gambling 2
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Medicine Products: